ArticleAsian Pacific journal of cancer prevention : APJCP2025
A Survival Analysis of Pediatric Acute Lymphoblastic Leukemia in Morocco.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a WHO's Global Initiative for Childhood Cancer pilot site, Morocco conducted a study on the overall survival rates of the six WHO index diseases. The objectives of this study were to estimate the survival rates for childhood acute lymphoblastic leukemia (ALL) diagnosed at Moroccan Pediatric Hematology and Oncology (PHO) centers, to identify factors of treatment failure, and to explore opportunities for improvement.
methodsThis retrospective study included children with ALL aged 0-15 years. Patients were monitored with active follow-up until March 31, 2023. The Kaplan Meier method was used to estimate survival rates, the log-rank test to compare survival, and the Cox model to identify prognostic factors.
resultsData included 425 patients; most were aged 1-10years (n=318, 74.9%), and males (n=239, 56.2%). The complete remission induction rate was 84%. One-, three- and five-year overall survival rates were 78.7%, 63.8% and 60.8%, respectively. In a multivariate Cox model regression, age group, phenotype, complete remission following induction and white blood cell count > 50,000/mm3 were statistically associated with survival. Children with T-cell ALL were also more likely to die compared to those with B-cell ALL (HR=2.33 p<0.001).
conclusionThe 5-year survival rate in our study was 60.8%, below Morocco's 80% target by 2030. Among 203 events, 86 were relapses, 34 resulted from treatment abandonment, and 55 from treatment-related toxicity. While relapse is the leading cause of treatment failure, prioritizing the reduction of treatment abandonment and toxicity-related mortality is a more feasible first step.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.